Telum Therapeutics, a biotechnology company leveraging proprietary metagenomic datasets, synthetic biology and generative AI to develop novel antimicrobial therapies, announced the successful completion of an €18 million Series A financing to advance its lead program targeting hospital-acquired bacterial .

Telum Therapeutics 是一家利用专有宏基因组数据集、合成生物学和生成式人工智能开发新型抗菌疗法的生物技术公司，该公司宣布成功完成1800万欧元的A轮融资，以推进其针对医院获得性细菌感染的主要研发项目。

pneumonia

肺炎

(HABP) and ventilator-associated bacterial pneumonia (VABP) caused by

由以下原因引起的医院获得性细菌性肺炎 (HABP) 和呼吸机相关性细菌性肺炎 (VABP)

Acinetobacter baumannii

鲍曼不动杆菌

.

。

AMR Action Fund led the financing round, with participation from new investor Inveready and continued support from existing investors Invivo Partners, CDTI with its SICC Innvierte, Clave Capital and Sodena.

AMR行动基金领投了此轮融资，新投资者Inveready参与投资，现有投资者Invivo Partners、CDTI（通过其SICC Innvierte项目）、Clave Capital和Sodena继续提供支持。

The investment from AMR Action Fund, the world’s largest venture capital fund dedicated exclusively to investing in urgently needed antimicrobial therapeutics and diagnostics, brings not only capital, but also deep domain expertise in antimicrobial resistance (AMR). The Fund’s support will enable Telum to advance its lead candidate through Phase 1 clinical development, generating critical safety and translational data to support subsequent stages of clinical evaluation..

来自AMR行动基金的投资不仅带来了资金，还带来了在抗菌素耐药性（AMR）领域的深厚专业知识。该基金是全球最大的专门投资于急需的抗菌治疗和诊断产品的风险投资基金。该基金的支持将使Telum能够推进其领先候选药物通过第一阶段临床开发，生成关键的安全性和转化数据，以支持后续阶段的临床评估。

Novel antibiotics in the fight against antimicrobial resistance

对抗抗菌素耐药性的新型抗生素

SANTERO announces a €8 million Series A funding round led by Newton Biocapital

SANTERO 宣布完成由 Newton Biocapital 领投的 800 万欧元 A 轮融资

Read news

阅读新闻

Telum’s lead program is designed to address severe infections caused by

Telum 的主要项目旨在应对由以下原因引起的严重感染：

Acinetobacter baumannii

鲍曼不动杆菌

, a multidrug-resistant Gram-negative pathogen associated with significant morbidity and mortality in hospitalized patients worldwide. Built on the Company’s proprietary APEX® platform, Telum is developing biologically derived, protein-based antimicrobial therapeutics with the potential to overcome key limitations of existing antibiotic approaches and expand treatment options for patients facing life-threatening infections..

，一种多重耐药革兰氏阴性病原体，与全球住院患者的高发病率和高死亡率相关。基于公司专有的APEX®平台，Telum正在开发生物源性的蛋白质类抗菌疗法，有望克服现有抗生素方法的关键局限性，并为面临危及生命的感染患者拓展治疗选择。

Dr. Henry Skinner, Chief Executive Officer of the AMR Action Fund, commented: “

AMR行动基金首席执行官亨利·斯金纳博士评论道：“

Acinetobacter baumannii

鲍曼不动杆菌

is one of the most formidable bacterial threats in modern medicine. It is clinically challenging, often resistant to first-line therapies, and a pathogen for which progress has been slow and di\icult to achieve. We are encouraged by Telum’s novel approach and pleased to support the team as they work to bring forward a new treatment option for patients with life-threatening infections.”.

“是现代医学中最具威胁性的细菌之一。它在临床上极具挑战性，往往对一线疗法产生耐药性，且针对该病原体的研究进展缓慢、难以取得突破。我们对Telum的创新方法感到鼓舞，并很高兴支持该团队，致力于为患者带来一种新的治疗选择，以应对危及生命的感染。”

Dr. Subhendu Basu, Chief Executive Officer of Telum Therapeutics, said: “We are delighted to welcome AMR Action Fund and Inveready as new investors in Telum. AMR Action Fund’s dedicated focus and deep expertise in antimicrobial resistance, together with the continued support of Invivo Partners, Clave Capital, CDTI-Innvierte and Sodena, reinforces our confidence in the potential of the APEX® platform to generate a new class of antimicrobial therapies for di\icult-to-treat infections.

Telum Therapeutics 首席执行官苏本杜·巴苏博士表示：“我们很高兴欢迎 AMR Action Fund 和 Inveready 成为 Telum 的新投资者。AMR Action Fund 在抗微生物药物耐药性领域的专注聚焦与深厚专长，加之 Invivo Partners、Clave Capital、CDTI-Innvierte 和 Sodena 的持续支持，进一步坚定了我们的信心，相信 APEX® 平台有潜力为难以治疗的感染开发出一类全新的抗微生物疗法。”

This financing provides a clear path to complete Phase 1 development of our lead program targeting .

这笔融资为我们针对[靶点/适应症]的主要项目的第一阶段开发提供了清晰的完成路径。

Acinetobacter baumannii

鲍曼不动杆菌

HABP/VABP, while also enabling us to advance our broader pipeline addressing both Gram-negative and Gram-positive pathogens.”

HABP/VABP，同时也使我们能够推进更广泛的研发管线，以应对革兰氏阴性和革兰氏阳性病原体。”

Dr. Laura Rodríguez, Partner at Invivo and Board member at Telum, commented: “Having supported Telum since its earliest stages, we are delighted to welcome AMR Action Fund as lead investor in this financing. Their participation is a strong validation of the progress achieved by the Company, the quality of its science, and the commitment of the team to tackling antimicrobial resistance.

Invivo合伙人兼Telum董事会成员劳拉·罗德里格斯博士表示：“自Telum初创阶段起，我们便一直为其提供支持。我们很高兴迎来AMR行动基金作为本轮融资的领投方。他们的参与是对公司所取得的进展、其科学成果的质量以及团队致力于应对抗微生物药物耐药性问题的坚定承诺的有力认可。”

We believe this round marks a defining milestone in Telum’s evolution, reinforcing its position within the global antimicrobial innovation ecosystem and equipping the Company with the resources, expertise and support needed to advance into the clinic.”.

我们相信，本轮融资标志着Telum发展进程中的一个重要里程碑，巩固了其在全球抗菌创新生态系统中的地位，并为公司提供了进入临床试验阶段所需的资源、专业知识和支持。

Dr. Roberto Díez, Founder and Chief Operating Officer of Telum Therapeutics, added: “Telum was founded with the vision of developing a new generation of antimicrobial therapies capable of combating some of the world’s most dangerous drug-resistant pathogens. This financing marks an important milestone for the Company and reflects the strength of our scientific platform, the progress of our lead program, and the growing recognition that innovative solutions are urgently needed to address the global threat of antimicrobial resistance.”.

Telum Therapeutics 的创始人兼首席运营官 Roberto Díez 博士补充道：“Telum 的创立愿景是开发新一代抗菌疗法，以对抗一些全球最危险的耐药病原体。此次融资标志着公司的一个重要里程碑，也反映了我们科学平台的实力、我们领先项目的进展，以及人们日益认识到迫切需要创新解决方案来应对抗菌素耐药性这一全球威胁。”

This financing brings together international and Spanish life sciences investors, technology-focused investment funds and public institutions committed to supporting innovation in healthcare. It also highlights the important role of Navarra’s innovation ecosystem in fostering the development of science-driven companies with global ambition..

此次融资汇聚了国际及西班牙的生命科学投资者、专注于科技领域的投资基金，以及致力于支持医疗保健创新的公共机构。这也凸显了纳瓦拉创新生态系统在培育具有全球雄心的科学驱动型企业发展方面的重要作用。

https://www.bionity.com/en/news/1189148/telum-therapeutics-secures-18-million-series-a-to-tackle-drug-resistant-hospital-pneumonia.html

https://www.bionity.com/en/news/1189148/telum-therapeutics-secures-18-million-series-a-to-tackle-drug-resistant-hospital-pneumonia.html

Study: Superbug MRSA infections less costly, but still deadly

研究：超级细菌MRSA感染成本较低，但仍致命

Read news

阅读新闻

Most read news

阅读最多的新闻

1

1

It may not just be what’s in ultra-processed foods, but how they’re made

问题可能不仅在于超加工食品中的成分，还在于其加工方式。

2

2

New drug could slow the development of Alzheimer’s

新药或可延缓阿尔茨海默病的进展

3

3

Mini-Brains from Patient Cells Point to Vitamin B3 as Treatment for Rare Childhood Disease

患者细胞衍生的迷你脑组织提示维生素B3可作为罕见儿童疾病的治疗手段

4

4

New antibiotics discovered to treat multi-resistant germs

发现新型抗生素以治疗多重耐药菌

5

5

Inducing cell death in pancreatic cancer cells

诱导胰腺癌细胞死亡

Topics

主题

Series A financing

A轮融资

Acinetobacter baumannii

鲍曼不动杆菌

pneumonia

肺炎

investments

投资

infectious diseases

传染病

infections

感染

gram-negative bacteria

革兰氏阴性菌

antimicrobial drugs

抗菌药物

antimicrobial resistance

抗菌药物耐药性

clinical development

临床开发

Show all

显示全部

Show less

显示更少

Organizations

组织

Telum Therapeutics

泰伦治疗公司